• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Fulvestrant: a review of its development, pre-clinical and clinical data.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Wardley, Andrew M
    Affiliation
    Department of Medical Oncology, Christie Hospital, Withington, Manchester, UK.
    Issue Date
    2002-05
    
    Metadata
    Show full item record
    Abstract
    Hormone therapy is the most important systemic treatment of hormone receptor-positive breast cancer at all stages. Selective oestrogen receptor modulators (SERMs), such as tamoxifen, the mainstay of hormone receptor positive breast cancer manipulation for many years, are limited by their agonist actions. Oestrogen-like activity of these drugs may stimulate cancer growth such as in the endometrium and is a mechanism of resistance in breast cancer. Fulvestrant, the first of a new class of drugs, an oestrogen receptor down regulator, may have advantages over tamoxifen in the treatment of oestrogen-dependent disease. The pre-clinical development and early clinical data of fulvestrant are reviewed. Fulvestrant was as effective as the aromatase inhibitor anastrazole in second-line advanced breast cancer. The phase III trial of fulvestrant versus tamoxifen, as first-line treatment for metastatic breast cancer, has completed accrual and is maturing. Fulvestrant has useful activity against breast cancer as well as a favourable side-effect profile and is likely to represent a useful addition to the fight against hormone dependent breast cancer. Its place will be better defined by ongoing clinical trials.
    Citation
    Fulvestrant: a review of its development, pre-clinical and clinical data. 2002, 56 (4):305-9 Int. J. Clin. Pract.
    Journal
    International Journal of Clinical Practice
    URI
    http://hdl.handle.net/10541/80258
    PubMed ID
    12074216
    Type
    Article
    Language
    en
    ISSN
    1368-5031
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    • Authors: Robertson JF
    • Issue date: 2004 Dec
    • Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    • Authors: Berry J
    • Issue date: 2005 Nov
    • Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
    • Authors: Sabnis G, Goloubeva O, Jelovac D, Schayowitz A, Brodie A
    • Issue date: 2007 May 1
    • Aromatase inhibitors and breast cancer.
    • Authors: Miller WR
    • Issue date: 2006 Mar
    • Are aromatase inhibitors superior to antiestrogens?
    • Authors: Howell A, Buzdar A
    • Issue date: 2005 Feb
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.